nach oben

Drugs

Erschienen in:

01.10.2002 | Adis New Formulation Profile

Extended- Release Methylphenidate (Ritalin® LA)

verfasst von: Katherine A. Lyseng-Williamson, Gillian M. Keating

Erschienen in: Drugs | Ausgabe 15/2002

Einloggen, um Zugang zu erhalten

Abstract

▴ An extended-release formulation of methylphenidate (Ritalin® LA), a CNS stimulant that inhibits dopamine and noradrenaline (norepinephrine) reuptake into presynaptic neurons, has been developed for use in patients with attention deficit/hyperactivity disorder (ADHD).
▴ In children with ADHD and healthy male adults, extended-release methylphenidate 20mg was rapidly absorbed and demonstrated two distinct peak plasma concentrations ≈4 hours apart. The absorption pharmacokinetics of extended-release methylphenidate 20mg, which closely mimics those of immediate-release methylphenidate 10mg given in two doses 4 hours apart, permits once-daily administration.
▴ In a 2-week randomised, double-blind, placebo-controlled trial in 134 evaluable children aged 6 to 12 years with ADHD, symptoms improved to a significantly greater extent with extended-release methylphenidate 10 to 40mg once daily than with placebo.
▴ Extended-release methylphenidate improved both inattention and hyperactivity symptoms and was effective in children with combined- (inattentive and hyperactive/impulsive) type or predominantly inattentive-type ADHD.
▴ In clinical trials, the safety and tolerability profiles of extended-release methylphenidate were consistent with that of the immediate-release formulation. 1 Use of a tradename is for product identification purposes only, and does not imply endorsement.

American Academy of Pediatrics Committee on Quality Improvement, Subcommittee on Attention-Deficit/Hyperactivity Disorder. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics 2000 May; 105(5): 1158–70CrossRef

Murray L, Patel DR. Treatment of attention-deficit hyperactivity disorder. Indian J Pediatr 2001 Jan; 68(1): 1–9PubMedCrossRef

Wilens TE, Biederman J, Spencer TJ. Pharmacotherapy of attention deficit hyperactivity disorder in adults. CNS Drugs 1998 May; 9(5): 347–56CrossRef

American Academy of Pediatrics Committee on Quality Improvement, Subcommittee on Attention-Deficit/Hyperactivity Disorder. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 2001 Oct; 108(4): 1033–44CrossRef

Safer DJ. Central stimulant treatment of childhood attention deficit hyperactivity disorder: issues and recommendations from a US perspective. CNS Drugs 1997 Apr; 7(4): 264–72CrossRef

Greenhill LL, Halperin JM, Abikoff H. Stimulant medications. J Am Acad Child Adolesc Psychiatry 1999 May; 38(5): 503–12PubMedCrossRef

Kimko HC, Cross JT, Abernethy DR. Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet 1999 Dec; 37(6): 457–70PubMedCrossRef

Findling RL, Dogin JW. Psychopharmacology of ADHD: children and adolescents. J Clin Psychiatry 1998; 59 Suppl. 7: 42–9

Novartis Pharmaceuticals Corp. Ritalin LA (methylphenidate HCL) product monograph. East Hanover (NJ): Novartis Pharmaceuticals Corp, 2002

10.

Markowitz JS, Patrick KS. Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disease. Clin Pharmacokinet 2001; 40(10): 753–72PubMedCrossRef

11.

Solanto M. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 1998; 94: 127–52PubMedCrossRef

12.

Wall SC, Gu H, Rudnick G. Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: amphetamine specificity for inhibition and efflux. Mol Pharmacol 1995; 47: 544–50PubMed

13.

Volkow ND, Wang GJ, Fowler JS, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 1998 Oct; 155(10): 1325–31PubMed

14.

Dougherty DD, Bonab AA, Spencer TJ, et al. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 1999 Dec 18–25; 354: 2132–3PubMedCrossRef

15.

Krause K-H, Dresel SH, Krause K, et al. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett 2000; 285: 107–10PubMedCrossRef

16.

Spencer T, Swanson J, Markabi S, et al. Pharmacodynamic and pharmacokinetic profiles of a new modified-release formulation of Ritalin in children with ADHD [poster]. 2000 Annual Meeting of the American Psychiatric Association; 2000 May 13–18; Chicago (IL)

17.

Wigal SB, Gupta S, Guinta D, et al. Reliability and validity of the SKAMP rating scale in a laboratory school setting. Psychopharmacol Bull 1998; 34(1): 47–53PubMed

18.

Spencer TJ, Biederman J, Harding M, et al. Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays? J Am Acad Child Adolesc Psychiatry 1996 Nov;35(11): 1460–9PubMedCrossRef

19.

Klein RG, Landa B, Mattes JA, et al. Methylphenidate and growth in hyperactive children: a controlled withdrawal study. Arch Gen Psychiatry 1988 Dec; 45(12): 1127–30PubMedCrossRef

20.

Klein RG, Mannuzza S. Hyperactive boys almost grown up: III. Methylphenidate effects on ultimate height. Arch Gen Psychiatry 1998 Dec; 45(12): 1131–4

21.

Kramer JR, Loney J, Ponto LB, et al. Predictors of adult height and weight in boys treated with methylphenidate for childhood behavior problems. J Am Acad Child Adolesc Psychiatry 2000 Apr; 39(4): 517–24PubMedCrossRef

22.

Biederman J, Quinn D, Wigal S, et al. Methylphenidate hydrochloride extended release capsules: once-daily therapy for ADHD [abstract no. NR334]. American Psychiatric Association 2002 Annual Meeting; 2002 May 18–23; Philadelphia (PA).

23.

Biederman J, Quinn D, Weiss M, et al. Methylphenidate hydrochloride extended-release capsules (Ritalin LA): a new once-daily therapy for ADHD [poster]. American Psychiatric Association 2002 Annual Meeting; 2002 May 18–23; Philadelphia (PA)

24.

Kelly KL, Rapport MD, DuPaul GJ. Attention deficit disorder and methylphenidate: a multi-step analysis of dose-response effects on children’s cardiovascular functioning. Int Clin Psychopharmacol 1988; 3: 167–81PubMedCrossRef

25.

Findling RL, Short EJ, Manos MJ, et al. Short-term cardiovascular effects of methylphenidate and adderall. J Am Acad Child Adolesc Psychiatry 2001 May; 40(5): 525–9PubMedCrossRef

26.

American Society of Health-System Pharmacists. Methylphenidate hydrochoride. AHFS drug information. Bethesda (MD): American Society of Health-System Pharmacists, 2001: 2282–6

27.

Wroblewski BA, Leary JM, Phelan AM, et al. Methylphenidate and seizure frequency in brain injured patients with seizure disorders. J Clin Psychiatry 1992 Mar; 53(3): 86–9PubMed

28.

Gross-Tsur V, Manor O, van der Meere J, et al. Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective? J Pediatr 1997 Jan; 130(1): 41–4

29.

Feldman H, Crumrine P, Handen BL, et al. Methylphenidate in children with seizures and attention-deficit disorder. Am J Dis Child 1989 Sep; 143(9): 1081–6PubMed

30.

Hemmer SA, Pasternak JF, Zecker SG, et al. Stimulant therapy and seizure risk in children with ADHD. Pediatr Neurol 2001 Feb; 24(2): 99–102PubMedCrossRef

31.

Patrick KS, Kilts CD, Breese GR. Synthesis and pharmacology of hydroxylated metabolites of methylphenidate. J Med Chem 1981; 24(10): 1237–40PubMedCrossRef

32.

Rappley MD. Safety issues in the use of methylphenidate: an American perspective. Drug Saf 1997 Sep; 17(3): 143–8PubMedCrossRef

33.

Masand PS, Tesar GE. Use of stimulants in the medically ill. Psychiatr Clin North Am 1996 Sep; 19(3): 515–47PubMedCrossRef

34.

Swanson JM, Flockhart D, Udrea D, et al. Clonidine in the treatment of ADHD: questions about safety and efficacy. J Child Adoles Psychopharmacol 1995; 5(4): 301–4CrossRef

35.

Maloney MJ, Schwam JS. Clonidine and sudden death. Pediatrics 1995; 96(6): 1176–7PubMed

36.

Ahmann PA, Waltonen SJ, Olson KA, et al. Placebo-controlled evaluation of Ritalin side effects. Pediatrics 1993 Jun; 91(6): 1101–6PubMed

37.

Barkley RA, McMurray MB, Edelbrock CS, et al. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics 1990 Aug; 86(2): 184–92PubMed

Titel: Extended- Release Methylphenidate (Ritalin® LA)
verfasst von: Katherine A. Lyseng-Williamson
Gillian M. Keating
Publikationsdatum: 01.10.2002
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 15/2002
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200262150-00012

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Extended- Release Methylphenidate (Ritalin® LA)

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 15/2002

Biapenem

Gefitinib

Prevention of Perinatal HIV Transmission

Pharmacological Strategies to Decrease Transfusion Requirements in Patients Undergoing Surgery

Budesonide (Entocort® EC Capsules)

Biapenem